News
Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...
Vertex Pharmaceuticals (VRTX) kicks off 2025 with 3% revenue growth, strong product launches like ALYFTREK & JOURNAVX, and raised guidance.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback